Mira Pharma Candidate Drug SKNY-1 Shows Early Pharmacokinetic Signals, but the Real Test Still Lies in Human Trials
A filing submitted to a U.S. securities regulator has put Mira Pharma’s SKNY-1 back on the early-stage drug development stage; but from animal pharmacokinetic data to clinical efficacy, there remains a distance that cannot be crossed with an optimistic narrative.